Establishing Community-Based Normal Distributions of Selected Urinary Biomarkers
This research study has been ongoing for 10 years and originally funded by the American Cancer Society. For the past 3 years it has been funded by the National Cancer institute but with a different focus. The three goals of this study are:
To improve the accuracy of screening tests for the diagnosis of prostate cancer.
Identify biomarkers that will predict how aggressive prostate cancer will be. The tests currently in use for screening for prostate cancer are the PSA blood test and digital rectal examination (DRE) of the prostate. When either or both of these tests are positive, a tissue biopsy of the prostate is recommended.
The third goal is to provide accurate information about how rapidly prostate cancers will become worse. To accomplish this we will study tissue and blood to identify proteins and genes that are present at high or low levels in prostate cancers that progress slowly versus those that progress more rapidly.